Wordt geladen...
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
BACKGROUND: Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) as a second potential mode of anti-tumor...
Bewaard in:
| Gepubliceerd in: | J Immunother Cancer |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5320726/ https://ncbi.nlm.nih.gov/pubmed/28239472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0220-y |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|